Pharma Industrial India Magazine - May-June 2024

analytical technology solutions, and Paralab will supply Bi - oXplorers and the PolyBLOCK Compact Automated Parallel Synthesis Platform in Spain and Portugal. Q How does the BioXplorer 400XL manage precise addi- tions of liquids and gases? Louise Madden: Launched June 2023, the BioXplorer 400XL and BioXplorer 400P are the latest products in H.E.L’s portfo - lio, further enabling efficient, cost-effective development and optimization of industrial bioprocesses. The BioXplorer 400 XL features 8 configurable bioreactors, which can be controlled independently or in parallel, allowing for fast optimization of critical parameters for aerobic fermen - tations. Its modular design unlocks the versatility to choose from a range of processing monitoring measures, and allows accurate and precise additions of liquids and gases, con - trolled by up to four sets of peristaltic pumps and up to two sets of in-house calibrated mass flow controllers respective - ly, and the multi-sparger approach can be used to maintain strict control of dissolved gas levels safely. The system can be controlled by our WinISO software, mon - itoring parameters on interest, automatically acting on them and recording experimental data, facilitating complete auto - mation of fermentation experiments. Q What impact does H.E.L Group aim to achieve in the bio- technology industry through its innovative solutions? Louise Madden: BioXplorers have a range of applications in the biotechnology industry, from reducing carbon emissions in syngas production to simulating the gut microbiome. Decarbonization using syngas fermentation is reducing car - bon emissions by exploiting organisms capable of convert - ing carbon-containing industrial waste gases into useful fuels and chemicals. The BioXplorer 400P enables high-pressure fermentation to drive up gas solubility, resulting in increased product yields. The bioreactors can also facilitate microbiome simulation. The gut microbiome has a significant impact on human health, but its dynamic and multicompartmental nature makes it difficult to study. BioXplorers can be configured to simulate the micro - biome, enabling research into the effects of probiotics, age, ill health, and shifts in microbiota. Q How does H.E.L Group ensure the flexibility and efficien - cy of its PolyBLOCK platform and how does its Parallel Synthesis Platform maximize laboratory productivity? Louise Madden: Building a library of potential candidate lead molecules with desired characteristics efficiently, requires a targeted parallel synthesis approach, where the ability to run multiple experiments simultaneously dramatically improves productivity. The PolyBLOCK platforms are highly versatile automated par - allel synthesis platforms, with either 4 or 8 independently con - trolled reactor zones, and a compact configuration designed to facilitate benchtop studies. Its modular layout enables ca - pabilities of the system to be easily expanded and adapted, and high-pressure variants with stainless steel and Hastelloy reactor options support the study of hydrogenations and oth - er similar reactions. This allows researchers to optimize re - action parameters in parallel, investigating multiple synthetic routes and identifying optimal conditions for scale-up, con - version efficiency, and economic viability. Q Any expansion plans or research measures H.E.L Group is planning to stay ahead of industry needs? Louise Madden: We work closely with research institutes and universities globally to develop new cutting-edge technolo - gies and stay ahead of industry needs. This includes our re - cent partnership with the Indian Institute of Technology Kan - pur to develop new testing laboratories to conduct research into battery storage, new chemistry development, and ther - mal characteristics. PHARMA INDUSTRIALINDIA · MAY-JUN 24 17 INTERVIEW